Kangstem Biotech Co. Ltd. (217730) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kangstem Biotech Co. Ltd. (217730:KRX), powered by AI.

Current Price
₩2,700
P/E Ratio
-24.2
Market Cap
253.9B
Sector
Healthcare
What is the Kangstem Biotech Co. Ltd. stock price forecast?

Kangstem Biotech Co. Ltd. is currently trading at ₩2,700. View real-time AI analysis on Alpha Lenz.

What is Kangstem Biotech Co. Ltd. insider trading activity?

View the latest insider trading data for Kangstem Biotech Co. Ltd. on Alpha Lenz.

What is Kangstem Biotech Co. Ltd.'s P/E ratio?

Kangstem Biotech Co. Ltd.'s P/E ratio is -24.2.

Kangstem Biotech Co. Ltd.

KRX · 217730
₩2,700-15(-0.55%)Market closedKRX regular session 09:00–15:30 KST
Ask about Kangstem Biotech Co. Ltd.'s future dividend policy...
Alpha Chat Insight

Kangstem Biotech Co. Ltd. trades at a P/E of -24.2 (undervalued) with modest ROE of -18.7%.

Ask for details

Company Overview

Kangstem Biotech Co. Ltd. is a biotechnology company that focuses primarily on the development and commercialization of stem cell therapies. The company's primary purpose is to leverage advanced stem cell technologies for innovative medical solutions, transforming regenerative medicine and offering new treatment options for various conditions. With a strong emphasis on research and development, Kangstem Biotech is instrumental in exploring the potential of stem cells in treating autoimmune diseases, skin conditions, and neurodegenerative disorders. Operating in the cutting-edge sector of biotechnology, Kangstem Biotech impacts both the healthcare and pharmaceutical industries by striving to introduce pioneering therapies that could significantly enhance patient outcomes. The company's role in the financial market is linked to its efforts in pushing the boundaries of medical science, attracting investors interested in the burgeoning field of biotech innovation. As a key player in a rapidly evolving industry, Kangstem Biotech contributes to scientific advancements and economic growth through its ongoing commitment to developing effective and sustainable medical treatments.

CEO나종천
SectorHealthcare
IndustryBiotechnology
Employees97

Company Statistics

FY 2025

Profile

₩253,946,202,300Market Cap
₩3,572,463,930Revenue
94.05MShares Out
97Employees

Margins

23.65%Gross
-245.33%EBITDA
-494.56%Operating
-293.00%Pre-Tax
-293.00%Net

Valuation

-24.23P/E
3.70P/B
71.08EV/Sales
-29.87EV/EBITDA
-20.58P/FCF

Growth (CAGR)

-39.71%Rev 3Yr
-17.12%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-15.23%ROA
-18.75%ROE
-14.51%ROIC

Financial Health

₩1,969,253,910Cash & Cash Equivalents
₩10,463,728,250Net Debt
18.00%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Kangstem Biotech Co. Ltd. (ticker: 217730) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 97 employees. Market cap is $253.9B.

The current price is ₩2,700 with a P/E ratio of -24.23x and P/B of 3.7x.

ROE is -18.75% and operating margin is -494.56%. Annual revenue is $3.6B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Kangstem Biotech Co. Ltd. (217730) Stock Forecast 2026 ₩2,700 — Price, Financials & Analyst Targets | Alpha Lenz